Abstract
Objective: To evaluate short-term effects of tolvaptan in patients hospitalized for refractory heart failure(HF). Methods and Results: Four patients(mean age 74.5+11.5years, male 75%, ischemic etiology 75%, left ventricular ejection fraction 36.5+12.0%) who received oral tolvaptan(15mg daily, 7 days) for refractory HF were observed before and at day 7. All patients resisted standard therapy including diuretics, carperitide, and inotropic agents. Tolvaptan reduced body weight(57.1±4.5kg to 54.2±4.9kg), though this difference was not significant(p=0.57).There were no significant difference between before and at day7 serum creatinine level(1.6±0.4 vs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
